Compare DIBS & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIBS | ANTX |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.7M | 172.9M |
| IPO Year | 2021 | 2022 |
| Metric | DIBS | ANTX |
|---|---|---|
| Price | $4.11 | $4.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $7.00 | $2.00 |
| AVG Volume (30 Days) | 260.8K | ★ 353.1K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.45 | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $89,620,000.00 | N/A |
| Revenue This Year | $3.12 | N/A |
| Revenue Next Year | $1.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.54 | N/A |
| 52 Week Low | $2.50 | $1.00 |
| 52 Week High | $6.62 | $6.91 |
| Indicator | DIBS | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.07 | 58.69 |
| Support Level | $3.95 | $3.91 |
| Resistance Level | $4.83 | $5.13 |
| Average True Range (ATR) | 0.21 | 0.36 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 9.41 | 80.00 |
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company has a single reportable and operating segment that contains one reporting unit, which consists of the company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.